We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01371968
Recruitment Status : Completed
First Posted : June 13, 2011
Last Update Posted : October 27, 2017
Malaysian Society of Anaesthesiologists
Information provided by (Responsible Party):
Lee Chew Kiok, University of Malaya

Brief Summary:
This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Condition or disease Intervention/treatment Phase
Airway Response Drug: alfentanil Not Applicable

Detailed Description:

The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids

The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia
Study Start Date : February 2011
Actual Primary Completion Date : August 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: alfentanil
patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods
Drug: alfentanil
Alfentanil is administered intravenously at the end of surgery.
Other Name: Rapifen

Primary Outcome Measures :
  1. Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Number of patient with airway complication [ Time Frame: after administration of alfentanil and within 1 min of LMA removal ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. ASA I and II patients
  2. Age 18 to 49 years old
  3. Minor elective day care surgery (> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids.

Exclusion Criteria:

  1. Potential difficult airway
  2. Reactive airway disease or sign and symptoms of upper respiratory tract infection.
  3. History of cardiac, pulmonary and renal diseases
  4. Body Mass Index > 30 kgm2.
  5. Risk of aspiration.
  6. Poor dentition with high risk of damage.
  7. Patient refusal.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01371968

Layout table for location information
University Malaya Medical Centre
Kuala Lumpur, Malaysia, 59100
Sponsors and Collaborators
University of Malaya
Malaysian Society of Anaesthesiologists
Layout table for investigator information
Principal Investigator: Lee Chew Kiok, MBBS Department of Anaesthesiogy, UMMC.
Layout table for additonal information
Responsible Party: Lee Chew Kiok, University of Malaya
ClinicalTrials.gov Identifier: NCT01371968    
Other Study ID Numbers: Alfentanil LMA
First Posted: June 13, 2011    Key Record Dates
Last Update Posted: October 27, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Keywords provided by Lee Chew Kiok, University of Malaya:
optimal dose
laryngeal mask airway
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anesthetics, Intravenous
Anesthetics, General